our CAP-XXXX, our platform us well quarter updates as Today, joining Good conference for our will for first on and afternoon, thank exosomes product, and you as technology. provide I XXXX lead call.
our the one by $XX Nippon securing in publication Lancet, of this the program, quarter, progress with first prestigious world. medical the II upfront result Duchenne program. Phase saw a for of to we million cash our in muscular HOPE-X partnership commercial in journals fund Phase dystrophy Further, made foremost, our and The bringing Shinyaku in have significant III most We highlighted
in II encourage clinical CAP-XXXX. I paper greater our in strengthen publication, Phase trial for that read HOPE-X trial Phase the a the as haven't you discuss If demonstrated and you so speaks the it will in of shall of to HOPE-X I detail clinical scientific rationale understanding results your do this few both please minutes. to III The positive
continue treatment value future Capricor. of invest muscular prudently We to for of program pillar in the dystrophy. with The boys our the the older of CAP-XXXX is near-term Duchenne
and around for States. active We the have a U.S. the experienced, markets Shinyaku in remain Nippon subsidiary, Pharma, our commercial key We world. and partnerships further seeking United partner its NS well-resourced in
is companies the for Our with partner talented goal to commercially to of program. us global prepare DMD expansion
exosome The of value bioengineered is pillar second program. our
this it more in have progress will by extremely being program on say made program. that future, are but to technology this We in the the detailed updates pleased suffice we platform
team assembled to a a quality, remain research, organization in and lean yet We capital world-class clinical maintain to have manufacturing operations, efficient. in we continue order
in near-term also We to equity conduct balance have are no strong are turbulent have and markets to equity an sheet these fortunate need fortunate very a to financing.
this of call million providing X in execute least at to runway report prior announced over years strategies. financials our summary Our on $XX to cash,
patients clinical Turning designed to to on States. study our approximately clinical to in is like update the Phase placebo-controlled United would trial. III double-blind, status Phase an I the randomized, our provide HOPE-X DMD of a III enroll program. XX HOPE-X
largely of treating the process who in patients exist. later few the are whom and very be non-ambulant therapeutic options disease will for We stage
in XX,XXX men best which required be to the the are per young boys market includes DMD U.S.A. patient of of corticosteroids. on our year patients medical over comprises This about population All therapy, X/X or and
XX anecdotal sites to the Lancet in HOPE-X runs of community. sites onboarding for in objective on and bring site. screening next patient data, more It publication the months. the patients strong actively now at actively our the in is first HOPE-X than several the reports our of for HOPE-X are patients, We the the enthusiasm are on Based and strength board the
Nippon payments, As potentially comes during million $XXX Capricor's the up with which, you with HOPE-X. paid more achieved, of in some Shinyaku course be of to agreement know, will if milestone
available companies younger population combining well-described We space limitations, inconsistent This slowly themselves upon clinical these many therapy is the approved and have for development. existing products coupon for options expand indication or material for and had valuable approved. patients become the FDA to drugs also, the Capricor hoped. a we has If opportunity that therapeutic substantial currently older need. is dystrophy. in that be a very to will qualify There past, there of pediatric CAP-XXXX the will even gene approval, more similarly a their for than in much nothing believe exon-skipping of have moving concept with multiple with retains unmet In assets which the the coupons any voucher have Duchenne is rare of these the Further, the boys, muscular CAP-XXXX and have rights.
Lastly, additional like to data is with FDA. our available, I goal discuss would the continue to to data registration becomes our path -- reiterate clinical to as that
technology. you give on would update an I our platform Finally, like to exosome
on multiple this We platform fronts. continue to advance
nanoparticle. believe safety cargo nature's The is better the using targeted aspect of directly delivering Let you and the communication should exosomes efficacy they than important can to be that exosome be vesicular receptors which lipid most a targeting molecule of extra They and me we manufactured a can attached. they far devices. cytoplasm are profile have are that remind capable into that a
but I'll the team the and meetings limited surface the targeting and or RNAs, are inhibitory our targeting platform publications. of the hard providing towards small a include, manufacturing vaccine capabilities of and are proteins work exosome small developing to, and And These be at high platform. not based capability Our on or with molecules color The bioengineered paradigm. siRNAs exosomes for payloads future the loading, extensive. both on therapeutics in platform moving along cost-effective our exosome options and scalable and more affinity is on platform within development expanding at of
strategy the our essential and capabilities objective III a the as a the results for These nonequity over on and and that As technology. partnership platform highly updates II well publication excellent reinforce team our want to our additional in of development and platform respected program In for as as technology. the to Phase of Phase always, a business partners on model, goals. enhancement delivered medical commercial conclusion, last manufacturing our continued further we and with of our exosome year, have DMD capital. our stay as finding of well DMD management partnering tuned the journal the include advancement exosome of advancement I
DMD strong we we quarter also the on the importance value partnerships clinical energy and exosome While approached we are currently capital, of recognize platform. second Through with a data, and of focused and HOPE-X, the optimism. and careful externally tremendous management
Over the and we at in several scientific advocacy delivery Boston months, including RNA few next nonviral program. focused plan and symposiums various on conferences, to high-profile present exosomes banking, our
We in on call Parent for Meeting CFO, I turning our for on now will financials. year. Project an update of over DMD Scottsdale June more a the annual at program the our be will also this in detailed Muscular A.J. Dystrophy the update to A.J.? be Bergmann, providing
